A phase I, open-label multi-center, dose escalation study of AMN107 [nilotinib] in combination with imatinib in adult patients with Ph+ chronic myelogenous leukemia in chronic phase following a sub-optimal response to imatinib mesylate
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2006
At a glance
- Drugs Imatinib; Nilotinib
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Pharmacogenomic
- 01 Aug 2006 New trial record.